These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 25681850)

  • 1. Experience with eslicarbazepine acetate as treatment for painful diabetic neuropathy.
    Garcia-Escrivà A; López-Herandez N; Lezcano M; Berenguer L
    Neurologia; 2016; 31(9):639-640. PubMed ID: 25681850
    [No Abstract]   [Full Text] [Related]  

  • 2. Eslicarbazepine acetate for a patient with highly resistant epicrania fugax.
    Cuadrado ML; Aledo-Serrano Á; Ruiz-Álvarez L
    Pain Pract; 2015 Jan; 15(1):E27. PubMed ID: 25560733
    [No Abstract]   [Full Text] [Related]  

  • 3. Umeclidinium bromide/vilanterol trifenatate, perampanel, and eslicarbazepine acetate.
    Hussar DA; Dharsi N
    J Am Pharm Assoc (2003); 2014; 54(4):450-2, 454-5. PubMed ID: 25063267
    [No Abstract]   [Full Text] [Related]  

  • 4. Eslicarbazepine Acetate: A New Improvement on a Classic Drug Family for the Treatment of Partial-Onset Seizures.
    Galiana GL; Gauthier AC; Mattson RH
    Drugs R D; 2017 Sep; 17(3):329-339. PubMed ID: 28741150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-year follow-up with eslicarbazepine acetate: a consecutive, retrospective, observational study.
    Correia FD; Freitas J; Magalhães R; Lopes J; Ramalheira J; Lopes-Lima J; Chaves J
    Epilepsy Res; 2014 Oct; 108(8):1399-405. PubMed ID: 25060997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eslicarbazepine acetate as a therapeutic option in a patient with carbamazepine-induced rash and HLA-A*31:01.
    Kay L; Willems LM; Zöllner JP; Reif PS; Klein KM; Rosenow F; Strzelczyk A
    Seizure; 2017 Apr; 47():81-82. PubMed ID: 28340402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: results of the 1-year ESLIBASE retrospective study.
    Villanueva V; Serratosa JM; Guillamón E; Garcés M; Giráldez BG; Toledo M; Salas-Puig J; López González FJ; Flores J; Rodríguez-Uranga J; Castillo A; Mauri JA; Camacho JL; López-Gomáriz E; Giner P; Torres N; Palau J; Molins A
    Epilepsy Res; 2014 Sep; 108(7):1243-52. PubMed ID: 24908564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fentanyl produces an anti-hyperalgesic effect through the suppression of sodium channels in mice with painful diabetic neuropathy.
    Tanaka K; Nakanishi Y; Sekino S; Ikegami M; Ikeda H; Kamei J
    Eur J Pharmacol; 2014 Jun; 733():68-74. PubMed ID: 24704555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Efficacy of Eslicarbazepine Acetate in Models of Trigeminal, Neuropathic, and Visceral Pain: The Involvement of 5-HT1B/1D Serotonergic and CB1/CB2 Cannabinoid Receptors.
    Tomić MA; Pecikoza UB; Micov AM; Stepanović-Petrović RM
    Anesth Analg; 2015 Dec; 121(6):1632-9. PubMed ID: 26465930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Exalief as a newer antiepileptic drug for adjunctive therapy of refractory partial-onset seizures].
    Ermolenko NA; Buchneva IA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(11):129-34. PubMed ID: 25629136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetic Neuropathy.
    Wilton TD
    S Afr Med J; 1972 Nov; 46(46):1757. PubMed ID: 4655765
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of voltage-gated sodium channel blockers in the treatment of chronic pain: Potential uses in clinical practice based on available evidence.
    Alcántara Montero A; Sánchez Carnerero CI
    Rev Esp Anestesiol Reanim (Engl Ed); 2018 May; 65(5):275-283. PubMed ID: 29496230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyponatremia following esclicarbazepine therapy.
    Gupta DK; Bhoi SK; Kalita J; Misra UK
    Seizure; 2015 Jul; 29():11-4. PubMed ID: 26076838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eslicarbazepine acetate: A novel agent for the adjunctive treatment of epilepsy.
    Owen RT
    Drugs Today (Barc); 2010 Jan; 46(1):23-31. PubMed ID: 20200693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol): double blind crossover trial.
    Rull JA; Quibrera R; González-Millán H; Lozano Castañeda O
    Diabetologia; 1969 Aug; 5(4):215-8. PubMed ID: 4902717
    [No Abstract]   [Full Text] [Related]  

  • 16. CNSB004 (Leconotide) causes antihyperalgesia without side effects when given intravenously: a comparison with ziconotide in a rat model of diabetic neuropathic pain.
    Kolosov A; Goodchild CS; Cooke I
    Pain Med; 2010 Feb; 11(2):262-73. PubMed ID: 20002322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From guideline to patient: a review of recent recommendations for pharmacotherapy of painful diabetic neuropathy.
    Ziegler D; Fonseca V
    J Diabetes Complications; 2015; 29(1):146-56. PubMed ID: 25239450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Carbamazepine in the treatment of diabetic neuropathy. Preliminary report].
    Ocaranza Ochoa J; Cervantes Amezcua A; Macias Torres V; Casillas Ochoa P; Perez Becerra JL
    Prensa Med Mex; 1968; 33(3):132-5. PubMed ID: 5760024
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of eslicarbazepine acetate on the pharmacokinetics of a combined ethinylestradiol/levonorgestrel oral contraceptive in healthy women.
    Falcão A; Vaz-da-Silva M; Gama H; Nunes T; Almeida L; Soares-da-Silva P
    Epilepsy Res; 2013 Aug; 105(3):368-76. PubMed ID: 23570863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Brief Introduction to the History and Controversies of Clinical Trials in Diabetic Neuropathy.
    Calcutt NA; Fernyhough P
    Int Rev Neurobiol; 2016; 127():3-8. PubMed ID: 27133141
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.